Phospho-IRAK4 (Thr345/Ser346) Antibody - #DF7567

(3)   (6)  
Product: Phospho-IRAK4 (Thr345/Ser346) Antibody
Catalog: DF7567
Description: Rabbit polyclonal antibody to Phospho-IRAK4 (Thr345/Ser346)
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 60 kDa; 52kD(Calculated).
Uniprot: Q9NWZ3
RRID: AB_2841060

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(86%), Sheep(100%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
Phospho-IRAK4 (Thr345/Ser346) Antibody detects endogenous levels of IRAK4 only when phosphorylated at Thr345/Ser346.
RRID:
AB_2841060
Cite Format: Affinity Biosciences Cat# DF7567, RRID:AB_2841060.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; Interleukin-1 receptor-associated kinase 4; Interleukin1 receptor associated kinase 4; IPD1; IRAK 4; IRAK-4; IRAK4; IRAK4 mutated form 1; IRAK4_HUMAN; LOC 51135; NY REN 64; NY REN 64 antigen; NY-REN-64; REN64; Renal carcinoma antigen NY-REN-64;

Immunogens

Immunogen:
Uniprot:

Q9NWZ3(IRAK4_HUMAN) >>Visit HPA database.

Gene(ID):
IRAK4(51135)
Sequence:
MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Horse
86
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q9NWZ3 As Substrate

Site PTM Type Enzyme
M1 Acetylation
K3 Acetylation
K3 Ubiquitination
T6 Phosphorylation Q9NWZ3 (IRAK4)
S8 Phosphorylation Q9NWZ3 (IRAK4)
K33 Ubiquitination
K34 Acetylation
S114 Phosphorylation Q9NWZ3 (IRAK4)
K115 Ubiquitination
S150 Phosphorylation Q9NWZ3 (IRAK4)
S151 Phosphorylation Q9NWZ3 (IRAK4)
S152 Phosphorylation Q9NWZ3 (IRAK4)
S157 Phosphorylation
T208 Phosphorylation Q9NWZ3 (IRAK4)
T209 Phosphorylation Q9NWZ3 (IRAK4)
K313 Ubiquitination
S336 Phosphorylation
K338 Ubiquitination
T342 Phosphorylation Q9NWZ3 (IRAK4)
T345 Phosphorylation Q9NWZ3 (IRAK4)
S346 Phosphorylation Q9NWZ3 (IRAK4)
T352 Phosphorylation Q9NWZ3 (IRAK4)
K400 Sumoylation
K416 Ubiquitination

PTMs - Q9NWZ3 As Enzyme

Substrate Site Source
P14598 (NCF1) T133 Uniprot
P14598 (NCF1) T138 Uniprot
P14598 (NCF1) T153 Uniprot
P14598 (NCF1) S288 Uniprot
P14598 (NCF1) S320 Uniprot
P14598 (NCF1) S345 Uniprot
P14598 (NCF1) S348 Uniprot
P14598 (NCF1) T356 Uniprot
P14598 (NCF1) S359 Uniprot
P14598 (NCF1) S370 Uniprot
P51617-4 (IRAK1) S376 Uniprot
P51617-1 (IRAK1) T387 Uniprot
P58753 (TIRAP) T28 Uniprot
Q96FA3 (PELI1) S70 Uniprot
Q96FA3 (PELI1) S76 Uniprot
Q96FA3 (PELI1) S78 Uniprot
Q96FA3 (PELI1) T80 Uniprot
Q96FA3 (PELI1) S82 Uniprot
Q96FA3 (PELI1) T86 Uniprot
Q96FA3 (PELI1) T127 Uniprot
Q96FA3 (PELI1) T288 Uniprot
Q96FA3 (PELI1) S293 Uniprot
Q9NWZ3 (IRAK4) T6 Uniprot
Q9NWZ3 (IRAK4) S8 Uniprot
Q9NWZ3 (IRAK4) S114 Uniprot
Q9NWZ3 (IRAK4) S150 Uniprot
Q9NWZ3 (IRAK4) S151 Uniprot
Q9NWZ3 (IRAK4) S152 Uniprot
Q9NWZ3 (IRAK4) T208 Uniprot
Q9NWZ3 (IRAK4) T209 Uniprot
Q9NWZ3 (IRAK4) T342 Uniprot
Q9NWZ3 (IRAK4) T345 Uniprot
Q9NWZ3 (IRAK4) S346 Uniprot
Q9NWZ3 (IRAK4) T352 Uniprot

Research Backgrounds

Function:

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation to form the Myddosome together with IRAK2. Phosphorylates initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates NCF1 and regulates NADPH oxidase activation after LPS stimulation suggesting a similar mechanism during microbial infections.

PTMs:

Phosphorylated.

Subcellular Location:

Cytoplasm.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Associates with MYD88 and IRAK2 to form a ternary complex called the Myddosome. Once phosphorylated, IRAK4 dissociates from the receptor complex and then associates with the TNF receptor-associated factor 6 (TRAF6), IRAK1, and PELI1; this intermediate complex is required for subsequent NF-kappa-B activation. Direct binding of SMAD6 to PELI1 prevents complex formation and hence negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-mediated gene expression. Interacts with IL1RL1.

Family&Domains:

Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. Pelle subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

References

1). The novel mechanism of human norovirus induced diarrhea: Activation of PKD2 caused by HuNoVs destroyed AQP3 expression through AP2γ in intestinal epithelial cells. Life sciences, 2024 (PubMed: 38103725) [IF=6.1]
2). Artemisinin attenuates perinatal inflammation and consequent oxidative stress in oligodendrocyte precursor cells by inhibiting IRAK-4 and IRAK-1. International Immunopharmacology, 2024 [IF=4.8]

Application: WB    Species: Rat    Sample: OPCs

Fig. 4. LPS-induced activation of the IRAK-4/IRAK-1/NF-κB signalling pathway in OPCs was inhibited by ART. a, b, c, d Western blotting was used to quantify the protein levels of p-IRAK-4, IRAK-4, p-IRAK-4/IRAK-4, p-IRAK-1, IRAK-1, p-IRAK-1/IRAK-1, phospho-NF-kB p65, NF-κB p65, and phospho-NF-kB p65/NF-κB p65 in 4 groups (the Ctrl, ART, LPS, and LPS + ART groups). The data are expressed as the means ± SEMs (n = 6/group) (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001).

Application: IF/ICC    Species: Rat    Sample: OPCs

Fig. 5. ART reduces NF-κB nuclear aggregation after LPS stimulation. a, b, c Immunofluorescence was used to compare the relative fluorescence of p-IRAK-4 (red) and p-IRAK-1 (red) in OPCs across several groups (the Ctrl, ART, LPS, and LPS + ART groups), and the proportion (%) of nuclear NF-κB p65 (red) was determined. DAPI staining is shown in blue. Scale bar = 50 μm. The data are presented as the means ± SEMs (n = 6). ****P < 0.0001 versus the indicated groups.
3). Pharmacological inhibition of IRAK1 attenuates colitis‐induced tumorigenesis in mice by inhibiting the inflammatory response and epithelial–mesenchymal transition. JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021 (PubMed: 34273909) [IF=3.6]

Application: WB    Species: Human    Sample: HCT‐116 cells

FIGURE 4 IRAK1/4 inhibitor treatment inhibits epithelial–mesenchymal transition (EMT) in mice by reducing TLR/IL‐1R‐mediated NF‐κB activation. (A) IRAK1/4 inhibitor treatment decreased the expression of phosphorylated IRAK4, IRAK1, and P65. (B) IRAK1/4 inhibitor treatment inhibits EMT induced by exposure to azoxymethane/dextran sodium sulfate (AOM/DSS). Values are expressed as mean±SD. # Significantly different compared with control, p<0.05; *significantly different compared with model, p <0.05

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.